“`html
Antimalarial Drug Resistance Threatens Global Progress, New WHO Report Warns
Table of Contents
A significant decline in global health funding coupled with rising antimalarial drug resistance is jeopardizing decades of progress against malaria, according to the latest report from the World Health Organization (WHO). The complete analysis, drawing on 2024 data from 80 endemic countries, underscores the urgent need for coordinated action and sustained investment to combat this escalating public health crisis.
The annual world malaria report is the result of a rigorous process, beginning with data collection and analysis by teams within the WHO’s Malaria and Neglected Tropical Diseases (MNT) division, in collaboration with national malaria programmes (NMPs) and WHO staff at all levels. The draft undergoes extensive review by external stakeholders and financial partners, with a transparent assessment of potential conflicts of interest. “External reviewers provided valuable feedback,which was carefully considered to refine the report,” a senior official stated.
Global Malaria Trends and the 2030 Target
This year’s report assesses trends in malaria morbidity and mortality worldwide, evaluating progress toward the milestones outlined in the WHO’s Global Technical Strategy for Malaria 2016-2030 (GTS). It also tracks investments in malaria programs, research, and interventions – encompassing prevention, diagnosis, treatment, and elimination efforts – alongside emerging biological threats.
A dedicated chapter highlights the growing concern surrounding antimalarial drug resistance, a challenge brought to the forefront by health leaders from African nations and global partners at the May 2025 World health Assembly. A high-level event, spearheaded by the Rwanda Ministry of Health and supported by organizations including the WHO, Medicines for Malaria Venture, the RBM Partnership to End Malaria, and Africa Centres for Disease Control and Prevention, emphasized the critical need for robust surveillance systems, rapid data sharing, and enduring financing to bolster malaria response efforts.
Funding Crisis Undermines Progress
Despite the focus on 2024 data, recent developments in 2025 are casting a shadow over global health initiatives. A considerable decrease in global development assistance for health – largely attributed to funding reductions from major donor nations – poses a significant threat to malaria control and elimination programs.
For two decades, the United States has been the leading government donor to humanitarian aid, development assistance, and multilateral development banks, primarily through the United States Agency for International Development (USAID). Though, proposed and enacted aid cuts from the US and other international donors are expected to severely undermine ongoing efforts. “The full impact of these cuts is still being evaluated, but the disruption to health operations worldwide is already widespread,” one analyst noted.
The burden of these setbacks will disproportionately affect children and younger populations. In response, some countries are stepping up to fill funding gaps, demonstrating the importance of domestic leadership and strategic resource allocation. The report further examines the impact of global development assistance funding in a dedicated section.
WHO Prioritizes New Guidance and Initiatives
The report also details selected priority initiatives of WHO/MNT, as well as newly developed and updated guidance released between 2024 and 2025. These initiatives aim to strengthen malaria control efforts in the face of evolving challenges, including drug resistance and funding constraints.
The convergence of rising drug resistance and dwindling financial support presents a formidable challenge to the global fight against malaria
